Citations

Clear

52 citation(s) found for "Sparks, R".

E-043 GLP-1 receptor agonists and risk of rupture of untreated intracranial arteriovenous malformations
McIntyre, M, Chen, H, Abarricia, J, Kakadiya, J, Rai, P, Azzam, A, Essibayi, M, Yedavalli, V, Dmytriw, A, Malhotra, A, Gandhi, D, Colasurdo, M, Lakhani, D, Abaricia, Jefferson O. , Kakadiya, Jay , Rai, Pranjal , Colasurdo, Marco

Mayo Clinic

SNIS 23rd Annual Meeting Electronic Poster Abstracts | July 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: A116.2-A117

10.1136/jnis-2026-snis.147 Get It

When estrogen sparks clotting: the lactoferrin-FXI link
Chen, Dong

Mayo Clinic

Blood | April 2, 2026 | Volume: 147 | Issue: 14 | Pages: 1518-1519

10.1182/blood.2025032335 | PMID 41926142 Get It

Longitudinal peripheral blood multi-omic profiling in seropositive individuals identifies immune endotypes and predictive models for future rheumatoid arthritis conversion
Inamo, Jun , Bylinska, Aleksandra, Smith, M. D., Wright, Christian D., Stephens, Tayte, Feser, Marie L. , Striebich, Christopher C. , O'Dell, James R., Sparks, J., Davis, J. Michael , Graf, Jonathan , McMahon, Maureen , Solow, E. Blair, Forbess, Lindsy J., Tiliakos, Athan N., Horowitz, Diane , James, Judith A., Holers, V. Michael , Deane, KD, Guthridge, Joel M., Zhang, F., Sparks, Jeffrey A. , Sparks, Jeffrey A , Guthridge, Joel M , Zhang, Fan , Smith, Miles, Vanderlinden, Lauren A. , Wright, Christian, O’Dell, James R., Davis, John M., Solow, E. Blair , Forbess, Lindsy, Fox, David A. , Danila, Maria I. , Kay, Jonathan , James, Judith A. , Guthridge, Joel M.

Mayo Clinic

No container title available | February 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.12.26346058 | PMID 41757162 Get It

Abstract Individuals who have serum elevations of anti-cyclic citrullinated protein (anti-CCP) antibodies are at risk for developing rheumatoid arthritis (RA), yet immunologic factors that lead to a transition from pre- to clinical RA remain unclear. Here, we used materials from anti-CCP antibody-positive individuals enrolled in a clinical trial that evaluated the efficacy of hydroxychloroquine to prevent clinical RA, and performed multi-modal single-cell profiling (transcriptome, surface proteins, T/B-cell receptor sequencing, and chromatin accessibility) on samples obtained at baseline and at RA onset in those who developed clinical RA (Converters) or follow-up point in matched Nonconverters. At both baseline and follow-up, Converters had expansions of peripheral helper T (Tph) cells and CD8 + T cells expressing GZMK and GZMB , along with elevated potentially autoreactive T-cell receptors in CD4 + T cells compared to Nonconverters. Induction of age-associated B cell signatures was observed in B cells of Converters prior to RA onset. Epigenetic profiling further identified chromatin accessibility changes in Converters over time, particularly within myeloid and NK cells. Lastly, predictive modeling using baseline immune features, including Tph cells, GZMK + XCL1 + CD8 + , and GZMB + CD57 + CD8 + T cells, together with clinical features such as anti-CCP3 levels, RF-positivity, and HLA shared epitope status, stratified RA risk and predicted time to onset. These findings define immune endotypes in pre-RA that could serve as targets for future preventive interventions and be used to stratify the risk of developing clinical RA in anti-CCP antibody-positive individuals.
A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis
Striebich, Christopher C. , Feser, Marie L. , O’Dell, James R., James, Judith A. , Sparks, Jeffrey A. , Davis, John M. , Graf, Jonathan , McMahon, Maureen , Solow, E. Blair , Forbess, Lindsy, Tiliakos, Athan, Schiopu, Elena , Horowitz, Diane , Strickland, C. , Arriens, Cristina , Grossman, Jennifer M. , Frazer‐Abel, Ashley , Fleischer, Chelsie , Greenleaf, Melissa E., York, Kate, Walker, Sarah , Keyes‐Elstein, Lynette, Byron, M., Goldmuntz, Ellen, Holers, V. Michael , Deane, Kevin D , James, Judith A , Sparks, Jeffrey A , Davis, John M , McMahon, Maureen , Kay, Jonathan , Fedler, Janel , Holers, V Michael , Tiliakos, Athan, Danila, Maria I. , Guthridge, Joel M. , Demoruelle, Mary Kristen , Bemis, Elizabeth A. , Fox, David A. , Mikuls, Ted R. , Walker, Sarah, Keyes-Elstein, Lynette

Mayo Clinic

Arthritis & Rheumatology | August 30, 2025 | Volume: 78 | Issue: 4 | Pages: 809-820

10.1002/art.43366 | PMID 40884017 Get It

Objective Individuals with serum elevations of anti–cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such at‐risk individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence. Methods In this phase 2 randomized trial, individuals at risk for RA with anti‐CCP3 ≥2 times the upper limit of normal (ULN) were assigned to receive HCQ or placebo for 12 months, with up to 24 months of postdrug follow‐up. The primary outcome was the development of clinical RA, as defined in the protocol, at 36 months. Secondary outcomes included safety, development of inflammatory arthritis (IA), and participant‐reported joint symptoms. Results Of 144 randomized participants, 71 were assigned to HCQ and 73 to placebo. In the modified intent‐to‐treat population, clinical RA occurred in 21 of 69 (30.4%) participants in the HCQ group and 24 of 73 (32.9%) in the placebo group. The risk of clinical RA at 36 months was 0.336 with HCQ and 0.394 with placebo (difference −0.058; 95% confidence interval −0.336 to 0.220; P = 0.52). Results for IA were similar. The occurrence and severity of joint symptoms were not observed to differ between groups. Adverse event incidence was similar between groups. Conclusion In this trial involving individuals with anti‐CCP3 levels ≥2 times the ULN, 12 months of HCQ did not prevent the development of clinical RA at 36 months. image
Rethinking psychological treatment targets for pediatric rumination syndrome: Clinical implications from a case series analysis
Anastasiadis, William A. , Gloe, Lilianne M. , Johnson-Kwochka, Annalee V. , Diest, Ashley M. Kroon Van , Lagges, Ann, Wagoner, Scott T. , Williams, Amy E. , Sparks, Brandon , Gilbert, Elaine

Mayo Clinic

JPGN Reports | August 7, 2025 | Volume: 6 | Issue: 4 | Pages: 382-386

10.1002/jpr3.70074 | PMID 41245029 Get It

Abstract Rumination syndrome (RS) is a common pediatric disorder of gut–brain interaction. However, a dearth of research on efficacious treatment to help guide clinical decision‐making remains. Thus, relying on well‐established treatment recommendations for other conditions with similar mechanisms or symptom profiles may be helpful; for example, conceptualizing RS treatment targets to address it as a “tic disorder of the gut” could be beneficial. To demonstrate the clinical utility of this conceptualization, we presented two cases that provide broad implications for treating pediatric RS. In both cases, akin to pediatric tic and related disorders, cognitive distress and physical discomfort were alleviated temporarily by rumination episodes. Thus, we recommend a targeted diagnostic assessment, including a functional analysis incorporating a transdiagnostic evaluation of symptoms. Close comanagement with specialty physicians and psychologists is also highly recommended. The patients represent complex yet standard cases seen in pediatric psychology outpatient clinics, suggesting the clinical utility of implications for psychologists and allied health professionals.
Digital Health Intervention to Promote Lifelong Specialized Care in Adults with Congenital Heart Disease: Study Design
Agarwal, Anushree , Valente, J. , Buernostro, Karina, Macholl, Katelyn , Mehta, J. L., Reddy, Keerthana , Manayan, Karina , Parang, Kim , Sparks, Aleah , Li, Kunyi , Ahuja, Pranav , Sun, Kevin , Payton, Kimberly , Norris, Mark D. , Moons, Philip , Okumura, Megumi J. , Marcus, Gregory M. , Gurvitz, Michelle , Bravo-Jaimes, Katia , Marcus, Gregory M , Valente, Joseph, Buenrostro, Karina , Mehta, Juhi, Bravo‐Jaimes, Katia , Reardon, Leigh Christopher

Mayo Clinic

No container title available | April 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.31.25324723 | PMID 40236434 Get It

Abstract Background Adults with congenital heart disease (ACHD) frequently experience gaps in lifelong ACHD specialty care, leading to preventable complications, hospitalizations, and premature mortality. However, effective, scalable, accessible, and sustainable strategies to reduce these gaps are lacking. Digital health offers potential solutions but requires a rigorous scientific approach in its design to address the needs of the target population. Objective To describe the development of a theory-based, community co-designed digital health intervention to improve lifelong ACHD care. Methods We integrated theory-based behavioral frameworks, semi-structured qualitative interviews with patients and clinicians, and a community-engaged approach to develop a digital health intervention for ACHD. The primary behavioral target was completing an ACHD specialist appointment. We conducted Capability, Opportunity, Motivation, and Behavior (COM-B)-guided semi-structured interviews with ACHD patients and clinicians to identify barriers to specialized care amenable to a digital intervention and patient-centered goals for the digital tool. The community partners helped develop key intervention objectives, create a theory-driven framework, and specify how each intervention component targets specific COM-B barriers. Results We interviewed 54 participants (37 ACHD patients and 17 clinicians) and engaged 21 community partners representing 4 advocacy organizations. Design objectives emphasized addressing patient loneliness, ensuring accessibility and credibility, and enabling scalability while centering patient perspectives. Participants identified four priorities: providing credible resources, uplifting patient voices, customizing to patient needs, and centering positivity and joy. The digital tool, named by community partners as Empower My Congenital Heart (EMCH), was designed within the web- and mobile-based, Apple- and Android-compatible, Eureka Digital Research platform (University of California, San Francisco). Key intervention components included educational modules, peer support, appointment planning nudges, and a digital medical passport. The EMCH’s theory-driven framework specifies how each intervention component targets specific COM-B barriers to specialized ACHD care. Conclusions The theory-driven, community co-designed EMCH digital tool is a rapidly scalable approach to improve guideline-recommended specialized ACHD care. Future studies will evaluate the acceptability, feasibility, effectiveness, and implementation outcomes to provide insight into a novel tool to reduce preventable morbidity and mortality in ACHD. Trial Registration The National Clinical Trial number for this study is NCT06581484 .
Tumour dosimetry across 6 cycles of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results from the VISION sub-study
Herrmann, Ken, Krause, Bernd‐Joachim, Chi, K.N., Fizazi, Karim , Eiber, M., Jentzen, Walter, Nguyen, Quang Ngoc , Blumenstein, Lars, Wilke, C., Sartor, Oliver , Morris, Michael J. , Bono, Johann S. de , Tagawa, Scott T. , Kurth, Jens , Laßmann, Michael , Sparks, R, Nguyen, Q, Rahbar, Kambiz

Mayo Clinic

Nuklearmedizin - NuclearMedicine | March 12, 2025 | Volume: 64 | Issue: 01 | Pages: 49-49

10.1055/s-0045-1804292 Get It

Associations of Fire Smoke and Other Pollutants With Incident Rheumatoid Arthritis and Rheumatoid Arthritis–Associated Interstitial Lung Disease
Kronzer, Vanessa L. , Yang, Yangyuna, Roul, Punyasha, Crooks, James , Crowson, Cynthia S. , Davis, John M. , Sparks, Jeffrey A. , Pierce, Jeffrey R. , O’Dell, Katelyn , Sauer, Brian C. , Baker, Joshua F. , Cannon, Grant W , Mikuls, Ted R , England, Bryant R , Sparks, Jeffrey A , Kronzer, Vanessa L , Davis, John M , Sauer, Brian C , Cannon, Grant W. , Baker, Joshua F. , Mikuls, Ted R. , England, Bryant R.

Mayo Clinic

Arthritis & Rheumatology | January 13, 2025 | Volume: 77 | Issue: 7 | Pages: 808-816

10.1002/art.43113 | PMID 39800945 Get It

Objective The aim of this study was to determine whether pollutants such as fire smoke–related particulate matter <2.5 μm (PM 2.5 ) are associated with incident rheumatoid arthritis (RA) and RA‐associated interstitial lung disease (RA‐ILD). Methods This patient–control study used Veterans Affairs (VA) data from October 1, 2009, to December 31, 2018. We identified patients with incident RA and RA‐ILD using validated algorithms, matching each patient to ≤10 controls on age, sex, and VA enrollment year. We obtained pollutants including fire smoke PM 2.5 , carbon monoxide, nitrogen oxides (NOx), ozone, overall PM 2.5 , PM 10 , and sulfur dioxide (SO 2 ) at least one year before the index date. We fit conditional logistic regression models to estimate adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for incident RA and RA‐ILD, adjusted for confounders. Results We identified 9,701 patients with incident RA (mean age 65 years, 86% male), including 531 patients with RA‐ILD (mean age 69 years, 91% male), and 68,852 matched controls. Fire smoke PM 2.5 was not associated with RA (aOR 1.07, 95% CI 0.92–1.23) but was associated with RA‐ILD (aOR 1.98, 95% CI 1.08–3.62, per 1 μg/m 3 ). Increased levels of NOx were associated with RA (aOR 1.16, 95% CI 1.06–1.27, highest vs lowest quartile). The highest quartiles of ozone (aOR 1.19, 95% CI 1.06–1.34) and PM 10 (aOR 1.25, 95% CI 1.10–1.43) were associated with seronegative RA. Carbon monoxide, overall PM 2.5 , and SO 2 were not, or negatively, associated with RA and RA‐ILD. Conclusion Increased fire smoke PM 2.5 was associated with RA‐ILD, whereas NOx, ozone, and PM 10 were associated with RA risk. Thus, air pollution may increase the risk of RA and RA‐ILD. image
Transgender Healthcare
Sparks, Payton J., Bozigar, Caden, Shah, Krish V., Wan, Rou , Uryga, Abigail, Nguyen, Antoinette T. , Li, Rena A. , Sparks, Payton J., Shah, Krish V., Galiano, Robert D.

Mayo Clinic

Annals of Plastic Surgery | December 12, 2024 | Volume: 94 | Issue: 1 | Pages: 128-133

10.1097/sap.0000000000004161 | PMID 39665456 Get It

Abstract This historical narrative presents a comprehensive historical journey delving into the diverse facets of gender identity and expression across ancient cultures. It explores these civilizations' perspectives on gender diversity, highlighting instances that challenged conventional gender norms. Transitioning to the modern era, the narrative examines the dynamic landscape of LGBTQ+ and trans movements, spotlighting influential figures whose advocacy has significantly influenced societal perceptions and advanced the rights of gender diverse individuals. Their contributions continue to shape contemporary affirming care practices. Exploring the emergence of gender-affirming surgery, the narrative highlights pioneering surgeons and original techniques employed in these transformative procedures. It shows the courage and innovation of early surgeons who laid the groundwork for contemporary practices. At the core of this historical narrative lies the pivotal role of plastic surgeons in gender-affirming care. It emphasizes the significance of a collaborative multidisciplinary approach among medical professionals to ensure comprehensive and patient-centered care for transgender individuals seeking affirming interventions. However, intertwined with this narrative are legislative barriers that have hindered progress in gender-affirming care. The narrative navigates these obstacles, highlighting their complexities and emphasizing the urgent need for sustained medical advocacy and legislative reforms to foster an inclusive healthcare landscape. Ultimately, this narrative stands as a testament to the ongoing struggle and resilience within the realm of gender-affirming care, shedding light on its profound impact on individuals' lives, emphasizing the ongoing need for compassionate, comprehensive, and inclusive healthcare practices.